LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

Home・Elenco Azioni・Johnson and Johnson

Johnson and Johnson

Chiusa

SettoreSettore sanitario

232.65 1.91

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

232.13

Massimo

233.99

Metriche Chiave
By Trading Economics
Entrata	119M 5.2B
Vendite	-502M 24B
P/E Media del settore	25.899 49.888
EPS	2.7
Rendimento da dividendi	2.31
Margine di Profitto	21.756
Dipendenti	138,200
EBITDA	182M 6.4B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+14.45% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.31% 2.38%
Utili prossimi	15 lug 2026
Prossima data del Dividendo	9 giu 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-35B 538B
Apertura precedente	230.74
Chiusura precedente	232.65

Notizie sul Sentiment di mercato

By Acuity

24%

76%

56 / 344 Classifica in Healthcare

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 apr 2026, 13:27 UTC

Acquisizioni, Fusioni, Takeovers

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 apr 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 apr 2026, 11:27 UTC

Utili

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 apr 2026, 19:38 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 14:13 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 12:57 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 11:19 UTC

Utili

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr 2026, 10:34 UTC

Utili

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 apr 2026, 10:20 UTC

Discorsi di Mercato

Utili

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 apr 2026, 10:20 UTC

Discorsi di Mercato

Utili

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 apr 2026, 10:20 UTC

Utili

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

14.45% in crescita

Previsioni per 12 mesi

Media 266.4 USD 14.45%

Alto 285 USD

Basso 250 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a Johnson and Johnson - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

56 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.